Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREvention of Macular EDema after cataract surgery
2012-004873-14Phase 3Completed
- Sponsor
- University Eye Clinic Maastricht
- Start
- Dec 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of bromfenac sodium, dexamethasone sodium phosphate, bevacizumab and triamcinolone acetonide in cystoid macular edema (CME), sponsored by University Eye Clinic Maastricht. Primary endpoint: Change in central subfield mean macular thickness at 6 weeks. Started Dec 2012; status: completed.
02
Drugs
bromfenac sodiumdexamethasone sodium phosphatebevacizumabtriamcinolone acetonide
03
Conditions
cystoid macular edema (CME)
Beyond the preview
Go deeper on 2012-004873-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004873-14.